Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia
Authors:
- Alessandro CostaACAlessandro Costa
- Carmelo GurnariCGCarmelo Gurnari
- Emilia ScalzulliESEmilia Scalzulli
- Laura CicconiLCLaura Cicconi
- Luca GuarneraLuca Guarnera
- Ida CarmosinoICIda Carmosino
- Raffaella CerrettiRCRaffaella Cerretti
- Maria Laura BisegnaMBMaria Laura Bisegna
- Saveria CapriaSCSaveria Capria
- Clara MinottiCMClara Minotti
- Anna Paola IoriAIAnna Paola Iori
- Lorenzo TorrieriLTLorenzo Torrieri
Open Access
Abstract
Background: The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has radically improved the prognosis of acute promyelocytic leukemia (APL), with cure rates above 80%. While relapse occurs in less than 20% of cases, addressing this issue remains challenging. Identifying effective salvage therapies for relapsed APL is crucial to improve patient outcomes. Methods: A retrospective analysis was performed on a multicentric cohort of 67 APL patients in first relapse, treated in three Italian hematology centers from June 1981 to November 2021. The overall survival (OS) and cumulative incidence of relapse (CIR) were calculated, and predictive factors were assessed using Cox regression models. Results: Overall, 61 patients (91%) received ATO ± ATRA (40.3%), chemo-based regimens (40.3%), or ATRA ± Gemtuzumab ozogamicin (GO) (10.4%). Complete remission (CR) was achieved in 98.2% of patients (molecular CR, n = 71.4%). With a median follow-up time of 54.5 months, the 5-year OS was 73% in the ATO ± ATRA group, 44% in the chemo-based group, and 29% in the ATRA ± GO group (p = 0.035). The 5-year OS rate was also higher for transplant recipients vs. non-recipients within the chemo-based cohort (50% vs. 33%, p = 0.017), but not in the ATO-based cohort (p = 0.12). ATO-based salvage therapy resulted in better OS in both univariate (p = 0.025) and multivariate analyses (p = 0.026). The 2-year CIR was higher in patients without molecular CR vs. patients in molecular CR (66% vs. 24%, p = 0.034). Molecular CR was a significant predictor of second relapse in both univariate (p = 0.035) and multivariate analyses (p = 0.036). Conclusions: Our findings support the efficacy of ATO-based therapies in first relapse of APL and confirm the achievement of molecular remission as an independent outcome predictor in both first and second APL relapse.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Promyelocytic Leukemia: Results of a Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2024
- Outcome of Patients With Relapsed Acute Promyelocytic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2024
- Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remissionBone Marrow Transplantation, 2020
- Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimensBritish Journal of Haematology, 2020
- Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapyAnnals of Hematology, 2018
- Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxideLeukemia & Lymphoma, 2016
- Autologous transplant remains the preferred therapy for relapsed APL in CR2Bone Marrow Transplantation, 2016
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialThe Lancet Oncology, 2015
- Understanding the molecular pathogenesis of acute promyelocytic leukemiaBest Practice & Research Clinical Haematology, 2014
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2013